onset of hereditary non polyposis colorectal cancer (HNPCC). We have extended our study that indicated that the CCND1 A variant may influence the age of onset of CRC in the Macedonian population only in patients who exhibit MSI tumors by a case control study of 331 randomly selected CRC patients and 101 controls without clinical diagnosis of CRC. We did not observe a significant difference in overall allelic frequencies and genotype distribution of affected and unaffected mutation carriers, but found a statistically significant risk of CRC in carriers of the CCND1 A allele when patients were grouped according to gender, age and MSI status. A higher risk was observed in patients with MSI-positive tumors and particularly in male patients under 60 years of age. The consequences of the above observation were reversed in female patients. These results indicate that the CCND1 A variant may enhance CRC progression through a pathway influenced by estrogens in colonic epithelia.
Key words: Cyclin D1; CCND1 G870A Polymorphism; Microsatellite instability (MSI); Colorectal cancer (CRC).
CCND1 IN MALE MSI+CRCs
Cyclin D1 plays a key role in cell cycle regulation, particularly in the transition from G1 to S phase, which is regulated by cyclin-dependent kinases (CDK). The predominant action of cyclin D1 is believed to result from interactions with CDK4 and/or CDK6 which promote phosphorylation and inactivation of retinoblastoma (RB) tumor suppressor protein, and thus facilitate of cell cycle progression [1] . Although somatic mutations in the Cyclin D1 gene (CCND1, also known as PRAD1) are rare, a common G→A polymorphism may influence cancer risk and outcome [2] [3] [4] [5] [6] [7] [8] [9] . The G870A polymorphism in exon 4 with in the spliced donor site results in two splice variants, "transcript a" preferentially associated with the G allele and truncated "transcript b" lacking exon 5, which is associated with the A allele [10] . However, individuals with the A/A genotype can still produce "transcript a" [11] , indicating that the 870-A allele is not completely penetrant for "transcript b" production. The "transcript b" results in a 274 amino acid product that lacks the C-terminal PEST domain and residue Thr 286 that regulates cyclin D1 stability, and the variant protein would be expected to have a longer half-life. However the half-life of cyclin D1b is only slightly greater than that of the fulllength variant (cyclin D1a) and cyclin D1b is a poor activator of CDK4 and RB phosphorylation [12, 13] . Nevertheless, cyclin D1b harbors an increased transforming capability (as compared to cyclin D1a) thus indicating that it may serve as a more potent oncogene in human cancers [12] [13] [14] [15] .
Microsatellite instability (MSI) in hereditary and in sporadic colorectal cancer (CRC) occurs through two mechanisms. In hereditary cases (e.g., hereditary non poly posis colorectal cancer-HNPCC), a germline mutation of one of the three main mismatch repair (MMR) genes (MLH1, MSH2, and MSH6), leads to mutational inactivation and deficient MMR. However, many CRCs show MSI without evidence of germline abnormalities. In sporadic CRC exhibiting MSI, instability in microsatellite se quences is often due to loss of expression of MMR genes (most commonly MLH1) that is caused by epigenetic silencing.
Most studies link the A allele to increased CRC risk and poor disease outcome, with the largest associations being observed with the A/A genotype. However, some studies have implicated the G allele with increased cancer risk [16] , while others have attributed no significant value to any allele of the G/A870 polymorphism [17] . There are conflicting reports on the implication of the CCND1 G870A polymorphism with the age of onset of HNPCC [2, 3, 11, 18] .
Our initial study on a limited number of patients from the Macedonian population indicated that the CCND1 A variant may influence the age of onset of CRC only in patients who exhibit MSI-positive tumors [19] . We have extended our study of the role of CCND1 polymorphism in tumorogenesis by a case control study of 331 randomly selected CRC patients and 101 controls without clinical diagnosis of CRC. The main aim of the study was to assess the CCND1 G870A polymorphism as a risk factor for CRC in the Macedonian population, and to elucidate the association between the CCND1 G870A polymorphism and
INTRODUCTION
Subjects. A total of 331 randomly selected patients with CRC and 101 control subjects from the Republic of Macedonia were studied ( Table 1 ). The average age of the patients was 61.25 ± 11.52 years, and 109 of them were less than 60 years old at diagnosis (average 51.13 ± 8.05 years). The tumors of 32 patients (18 of whom were younger than 60 years at diagnosis) showed MSI. The control subjects consisted of 101 individuals (average age 74.52 ± 10.46) without any history of malignant disease. Samples from the control subjects have been used previously for analysis of numerous genetic markers and were shown to be in Hardy-Weinberg equilibrium [19, 20] .
Detection of the G870A Polymorphism. Genomic DNA was isolated from peripheral blood (EDTA was used as anticoagulant) and tumors using Proteinase K digestion/ phenol-chloroform extraction and ethanol precipitation. The G870A polymorphism was detected by polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP) analysis using the following primers: 5'-TAC TAC CGC CTC ACA CGC TTC C-3' and 5'-TTG GCA CCA GCC TCG GCA TTT C-3'. The 135 bp PCR fragment was cleaved with the HpaII restriction enzyme and the digestion products were separated by electrophoresis on a 10% non denaturing polyacrylamide gel (Figure 1 ). 
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RESULTS
We did not observe a significant difference in overall allelic frequencies and genotype distribution of affected and unaffected mutation carriers {(A allele 0.533 for patients and 0.5 for controls; p = 0.41); (AA 30.21%, AG 46.22%, GG 23.57% for patients and AA 24.75%, AG 50.50%, GG 24.75% for controls; p = 0.29)}. However, the A allele frequency was higher (0.533) in our population than in numerous Caucasian populations (0.41-0.43) [16] (Table  2) . No significant correlation was found between the CCND1 genotype and Dukes stage, tumor differentiation or location, or preoperative carcinoembryonic antigen (CEA) level.
When the patients were stratified according to gender, age and MSI status (Tables 3 and 4) , we detected statistically significant risk of CRC in MSIpositive carriers of the CCND1 A allele (OR 2.3644; 95% CI: 1.0291<OR <5.4327; p = 0.0396) and MSIpositive carriers of the CCND1 A allele under 60 years of age (OD 3.8; 95% CI: 1.3516<OR<10.6837; p = 0.0082), which confirmed our previous results [19] . Most of this effect was confined to male patients with MSI-positive tumors (OD 5.5873; 95% CI: 1.6794<OR<18.5886; p = 0.0034) and in particular, male patients with MSI-positive tumors under 60 years of age (OD 10.6667; 95% CI: 2.3767<OR<47.8728; p = 0.0006). These trends were not observed in the female patients.
DISCUSSION
Although the molecular basis of HNPCC is well known, there is no explanation for the wide range of phenotypes observed, e.g., the wide variety in age of onset (19- 
CCND1 IN MALE MSI+CRCs
HNPCC phenotype. The first genetic modifier reported to be associated with age of onset in HNPCC was the CCND1 G870A polymorphism [2, 3] , but other studies failed to detect any significant association in a larger HNPCC population [11, 18] (Table 5) . We correlated the CCND1 G870A polymorphism with MSI status of the tumors and observed a statistically significant risk of CRC in MSI-positive carriers of the CCND1 A allele. After stratification by gender and age at diagnosis, we observed increased risk in male patients and particularly those under 60 years of age, as indicated by the increase of the ORs. The consequences of the above observation were reversed (although statistically not significant) in female patients (Tables 3 and 4 ). The effect of the CCND1 A allele on the risk of CRC apparently differs by gender which could be ex plained by the sex hormone divergence. The CCND1 870A variant may enhance CRC progression through a cell signalling pathway influenced by estrogens in colonic epithelia. It is well known that induction of cyclin D1 , and seems to be essential for maintenance of cellular homeostasis and for driving cellular differentiation in the colon [24, 25] . The fact that ERα, the predominant ER subtype in the human colon, is significantly decreased in CRCs compared with normal mucosa, led to our assumption that estrogen has a protective role in the regulation of colon tumor growth and CRC development. Indeed, the risk of both CRC and adenoma associated with a family history of CRC may be augmented by the CCND1 G870A genotype [5] . Moreover, the A870G genotype appears to enhance the protective effect of postmenopausal estrogen use on the development of colorectal neoplasia, whereas there was no effect of postmenopausal hormone use among those with the GG genotype [5] . Our findings led us to conclude that the CCND1 AA genotype may have a modifying effect in decreasing the age of onset in HNPCC, but only in males since they lack the protective effect of estrogen. If these results can be replicated in other case/control studies, the CCND1 G870A variant could be used in the future to provide additional information in genetic counseling of families with MSI-positive tumors.
